Categories Earnings, Health Care

Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot

— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.

— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.

Regeneron reports Q4 2019 earnings results

— Net product sales were $1.28 billion.

— EYLEA net product sales in the US were $1.22 billion.

— Sanofi and Bayer collaboration revenues were $748 million.

— R&D expenses totaled $683 million.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

IPO News: What to look for when Elevation Oncology makes its Wall Street debut

The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have

American Airlines (AAL): Here’s what may or may not work for this airline stock

Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top